<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
<journal-id journal-id-type="publisher-id">hmg</journal-id>
<journal-id journal-id-type="hwp">hmg</journal-id>
<journal-title-group>
<journal-title>Human Molecular Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-6906</issn>
<issn pub-type="epub">1460-2083</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26936821</article-id>
<article-id pub-id-type="pmc">5062588</article-id>
<article-id pub-id-type="doi">10.1093/hmg/ddw074</article-id>
<article-id pub-id-type="publisher-id">ddw074</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>mGlu<sub>5</sub> positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gogliotti</surname>
<given-names>Rocco G.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Senter</surname>
<given-names>Rebecca K.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rook</surname>
<given-names>Jerri M.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghoshal</surname>
<given-names>Ayan</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zamorano</surname>
<given-names>Rocio</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malosh</surname>
<given-names>Chrysa</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="af4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stauffer</surname>
<given-names>Shaun R.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="af4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="af5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bridges</surname>
<given-names>Thomas M.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bartolome</surname>
<given-names>Jose M.</given-names>
</name>
<xref ref-type="aff" rid="af6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Daniels</surname>
<given-names>J. Scott</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jones</surname>
<given-names>Carrie K.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lindsley</surname>
<given-names>Craig W.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="af4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>P. Jeffrey</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="af3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niswender</surname>
<given-names>Colleen M.</given-names>
</name>
<xref ref-type="aff" rid="af1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="af3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="af1"><sup>1</sup>Department of Pharmacology and</aff>
<aff id="af2"><sup>2</sup>Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA,</aff>
<aff id="af3"><sup>3</sup>Vanderbilt Kennedy Center,</aff>
<aff id="af4"><sup>4</sup>Department of Chemistry and</aff>
<aff id="af5"><sup>5</sup>Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA and</aff>
<aff id="af6"><sup>6</sup>Neuroscience Medicinal Chemistry, Janssen Research and Development, Jarama 75A., Toledo 45007, Spain</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">*To whom correspondence should be addressed. Email: <email>colleen.niswender@vanderbilt.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>5</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>25</volume>
<issue>10</issue>
<fpage>1990</fpage>
<lpage>2004</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>4</day>
<month>2</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="ddw074.pdf"></self-uri>
<abstract>
<p>Rett syndrome (RS) is a neurodevelopmental disorder that shares many symptomatic and pathological commonalities with idiopathic autism. Alterations in protein synthesis-dependent synaptic plasticity (PSDSP) are a hallmark of a number of syndromic forms of autism; in the present work, we explore the consequences of disruption and rescue of PSDSP in a mouse model of RS. We report that expression of a key regulator of synaptic protein synthesis, the metabotropic glutamate receptor 5 (mGlu<sub>5</sub>) protein, is significantly reduced in both the brains of RS model mice and in the motor cortex of human RS autopsy samples. Furthermore, we demonstrate that reduced mGlu<sub>5</sub> expression correlates with attenuated DHPG-induced long-term depression in the hippocampus of RS model mice, and that administration of a novel mGlu<sub>5</sub> positive allosteric modulator (PAM), termed VU0462807, can rescue synaptic plasticity defects. Additionally, treatment of <italic>Mecp2</italic>-deficient mice with VU0462807 improves motor performance (open-field behavior and gait dynamics), corrects repetitive clasping behavior, as well as normalizes cued fear-conditioning defects. Importantly, due to the rationale drug discovery approach used in its development, our novel mGlu<sub>5</sub> PAM improves RS phenotypes and synaptic plasticity defects without evoking the overt adverse effects commonly associated with potentiation of mGlu<sub>5</sub> signaling (i.e. seizures), or affecting cardiorespiratory defects in RS model mice. These findings provide strong support for the continued development of mGlu<sub>5</sub> PAMs as potential therapeutic agents for use in RS, and, more broadly, for utility in idiopathic autism.</p>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>Autism Speaks <named-content content-type="funder-id">http://dx.doi.org/10.13039/100000073</named-content></funding-source>
</award-group>
<award-group id="funding-2">
<funding-source>National Institutes of Health <named-content content-type="funder-id">http://dx.doi.org/10.13039/100000002</named-content></funding-source>
<award-id>R21 MH102548</award-id>
<award-id>R01 NS031373</award-id>
</award-group>
<award-group id="funding-3">
<funding-source>Rettsyndrome.org</funding-source>
</award-group>
<award-group id="funding-4">
<funding-source>Rettsyndrome.org</funding-source>
</award-group>
<award-group id="funding-5">
<funding-source>Vanderbilt University <named-content content-type="funder-id">http://dx.doi.org/10.13039/100006537</named-content></funding-source>
</award-group>
<award-group id="funding-6">
<funding-source>Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>